Literature DB >> 24664486

Implications of functional proteomics in breast cancer.

Young Kwang Chae1, Ana Maria Gonzalez-Angulo.   

Abstract

Breast cancer is one of the major public health problems of the Western world. Recent advances in genomics and gene expression-profiling approaches have enriched our understanding of this heterogeneous disease. However, progress in functional proteomics in breast cancer research has been relatively slow. Allied with genomics, the functional proteomics approach will be important in improving diagnosis through better classification of breast cancer and in predicting prognosis and response to different therapies, including chemotherapy, hormonal therapy, and targeted therapy. In this review, we will present functional proteomic approaches with a focus on the recent clinical implications of utilizing the reverse-phase protein array platform in breast cancer research.

Entities:  

Keywords:  Breast cancer; Functional proteomics; Predictive marker; Prognostic marker

Mesh:

Substances:

Year:  2014        PMID: 24664486      PMCID: PMC3983827          DOI: 10.1634/theoncologist.2013-0437

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  57 in total

Review 1.  Mechanism and function of deubiquitinating enzymes.

Authors:  Alexander Y Amerik; Mark Hochstrasser
Journal:  Biochim Biophys Acta       Date:  2004-11-29

Review 2.  Lapatinib in breast cancer: clinical experiences and future perspectives.

Authors:  M Giampaglia; V E Chiuri; A Tinelli; M De Laurentiis; N Silvestris; V Lorusso
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

3.  Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.

Authors:  Snježana Ramić; Ksenija Asić; Melita Perić Balja; Frane Paić; Vesna Benković; Fabijan Knežević
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

4.  Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Authors:  Fiona M Blows; Kristy E Driver; Marjanka K Schmidt; Annegien Broeks; Flora E van Leeuwen; Jelle Wesseling; Maggie C Cheang; Karen Gelmon; Torsten O Nielsen; Carl Blomqvist; Päivi Heikkilä; Tuomas Heikkinen; Heli Nevanlinna; Lars A Akslen; Louis R Bégin; William D Foulkes; Fergus J Couch; Xianshu Wang; Vicky Cafourek; Janet E Olson; Laura Baglietto; Graham G Giles; Gianluca Severi; Catriona A McLean; Melissa C Southey; Emad Rakha; Andrew R Green; Ian O Ellis; Mark E Sherman; Jolanta Lissowska; William F Anderson; Angela Cox; Simon S Cross; Malcolm W R Reed; Elena Provenzano; Sarah-Jane Dawson; Alison M Dunning; Manjeet Humphreys; Douglas F Easton; Montserrat García-Closas; Carlos Caldas; Paul D Pharoah; David Huntsman
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069

5.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Authors:  Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo A Ferrando; Per Malmström; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

7.  Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Authors:  Julia D Wulfkuhle; Daniela Berg; Claudia Wolff; Rupert Langer; Kai Tran; Julie Illi; Virginia Espina; Mariaelena Pierobon; Jianghong Deng; Angela DeMichele; Axel Walch; Holger Bronger; Ingrid Becker; Christine Waldhör; Heinz Höfler; Laura Esserman; Lance A Liotta; Karl-Friedrich Becker; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

8.  Molecular imaging of proteins in tissues by mass spectrometry.

Authors:  Erin H Seeley; Richard M Caprioli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-05       Impact factor: 11.205

9.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

Review 10.  Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue.

Authors:  Ning Qing Liu; René B H Braakman; Christoph Stingl; Theo M Luider; John W M Martens; John A Foekens; Arzu Umar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-05-30       Impact factor: 2.673

View more
  3 in total

Review 1.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

2.  Assessing the performance of genome-wide association studies for predicting disease risk.

Authors:  Jonas Patron; Arnau Serra-Cayuela; Beomsoo Han; Carin Li; David Scott Wishart
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

Review 3.  Breast cancer in the era of integrating "Omics" approaches.

Authors:  Claudia Rossi; Ilaria Cicalini; Maria Concetta Cufaro; Ada Consalvo; Prabin Upadhyaya; Gianluca Sala; Ivana Antonucci; Piero Del Boccio; Liborio Stuppia; Vincenzo De Laurenzi
Journal:  Oncogenesis       Date:  2022-04-14       Impact factor: 6.524

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.